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A B S T R A C T
The high prevalence of sleep disturbance in neurodegenerative and psychiatric conditions is often interpreted as
evidence for both sleep’s sensitivity to and causal involvement in brain pathology. Nevertheless, how and which
aspects of sleep contribute to brain function remains largely unknown. This review provides a critical evaluation
of clinical and animal literature describing sleep and circadian disturbances in two distinct conditions and an-
imal models thereof: Alzheimer’s disease (AD) and schizophrenia. Its goal is to identify commonalities and
distinctiveness of specific aspects of sleep disturbance and their relationship to symptoms across conditions.
Despite limited standardisation, data imply that reductions in sleep continuity and alterations in sleep timing are
common to AD and schizophrenia, whereas reductions in REM sleep and sleep spindle activity appear more
specific to AD and schizophrenia, respectively. Putative mechanisms underlying these alterations are discussed.
A standardised neuroscience based quantification of sleep and disease-independent assessment of symptoms in
patients and animal models holds promise for furthering the understanding of mechanistic links between sleep
and brain function in health and disease.
1. Introduction
This review is inspired by and is a critical reaction to the Innovative
Medicines Initiative PRISM project, the focus of this Special Edition
(Kas et al. 2018, this edition; http://www.imi.europa.eu/projects-
results/project-factsheets/prism). While not concentrating on sleep
biology per se, PRISM is an early practical attempt to redefine tradi-
tionally defined diagnoses of central nervous system (CNS) disease (in
this case Alzheimer’s disease and schizophrenia) based on more quan-
titative biological phenotypes. The work of PRISM builds on other ef-
forts such as the Research Domain Criteria initiative (Insel et al., 2010),
a NIMH-sponsored attempt to develop a modern, research-based tax-
onomy of mental disease. Such effort is bolstered by an increasing
scientific uneasiness that traditional neuropsychiatric diagnostic
boundaries may be impeding discovery of more impactful therapies for
patients. The goal of PRISM is of appreciable scientific merit; however,
such reconstructive approaches are not without technical and con-
ceptual challenge. The aim of this review is to exemplify sleep dis-
turbance as a potential quantitative biological phenotype in this con-
text, and to assess the current utility of such work for redefining
diagnostic boundaries of Alzheimer’s disease (AD) and schizophrenia
and the understanding of the contribution of sleep disturbance to
symptoms across these diseases.
Within the general population, the subjective experience of sleep
and its disturbance is one of the most significant determinants of quality
of life (Strine and Chapman, 2005). Sleep disturbance is also amongst
the most prevalent neuropsychiatric symptoms (NPS) in a wide range of
psychiatric and neurological disorders, such as AD, Parkinson’s disease,
major depression, bipolar disorder and schizophrenia (Baglioni et al.,
2016; Sutton, 2014). However, matters of on-going debate are whether
sleep disturbance should be considered primary or secondary compo-
nents of such disorders, to what extent it contributes to onset and
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exacerbation of other symptoms, and whether it can be used as bio-
marker of the diseases (Musiek and Holtzman, 2016; Winokur, 2015;
Yaffe et al., 2014; Kang et al., 2017). How sleep disturbance has actu-
ally been measured in previous studies is a vital consideration, as sev-
eral approaches have been used with different limitations in their
ability to provide information of appropriate complexity and utility.
This review will argue that an attempt to delineate a more biologically
driven reclassification of neurological and psychiatric diseases, such as
AD and schizophrenia, must pay more attention to parameters of sleep
disturbance and make more effort to measure these parameters at the
appropriate level of resolution in a co-ordinated manner in conjunction
with neuropsychiatric assessment.
2. Alzheimer’s disease and schizophrenia: clinical presentation
and current diagnosis
2.1. Alzheimer’s disease
First described by Alois Alzheimer in 1907 (Cipriani et al., 2011),
AD is a progressive neurodegenerative condition that represents the
majority of diagnosed dementia cases. A classic presentation of AD
would typically be an older person who complains of subjective
memory problems, or a significant other/carer does on their behalf
(Albert et al., 2011). These problems may initially be related to episodic
or autobiographical memories, but over a period of years will even-
tually involve most aspects of function necessary for daily living
(https://www.alz.org/alzheimers_disease_stages_of_alzheimers.asp, ac-
cessed 8/5/18; El Haj et al., 2015; Tromp et al., 2015). Clinical diag-
nosis of probable AD is currently based on presentation of symptoms.
Diagnosis is principally determined by the progressive worsening of
memory accompanied by changes in other cognitive domains, such as
language, motor skills or perception (McKhann et al., 1984), which
cannot be explained by other factors. Furthermore, other NPS such as
apathy, avolition and emotional and social withdrawal may be promi-
nent features in AD (Reichman and Negron, 2001). Recent studies
pointed that NPS, including sleep disturbance, represent a risk factor to
develop dementia (Bidzan et al., 2017; Frohnhofen et al., 2017). Neu-
rologists have long recognised that AD is by no means a unitary disease
that afflicts all patients equivalently, with empirical evidence sug-
gesting the existence of several subtypes, such as posterior cortical and
logopenic aphasic variants (Elahi and Miller, 2017).
In-life diagnosis of probable AD can be confirmed post-mortem by
the presence in the brain of amyloid plaques and tau neurofibrillary
tangles (Bourdenx et al., 2017). Findings suggest that deposition of
neurofibrillary tangles relates more consistently with symptomatic
complaints than do amyloid plaques (Theofilas et al., 2017). Plaques
and tangles largely show stereotypical patterns of deposition (Braak and
Braak, 1991), suggesting that some brain regions and/or networks may
be more vulnerable to pathology (Arendt et al., 2017; Gotz et al., 2009;
Hu et al., 2017; Oh et al., 2016; Stranahan and Mattson, 2010; Wang
et al., 2016). There is increasing evidence suggesting that tangles
spread throughout the brain in a manner consistent with underlying
neuroanatomical connectivity (Hanger et al., 2014; Jucker and Walker,
2013; Medina and Avila, 2014; Nizynski et al., 2017). Research ex-
ploring the propagative nature of AD neuropathology has been greatly
facilitated by the recent availability of both amyloid and tau protein
PET ligands (Blennow et al., 2015; Dani et al., 2016; Mathis et al., 2017;
Roberts et al., 2017), which now allow for in vivo longitudinal assess-
ment of neuropathology in patients. Future diagnosis (and prognostic
evaluation) of AD will certainly employ more sophisticated use of
amyloid and tau PET imaging technologies to determine subtypes of
disease based on patterns and progression of neuropathological de-
positions (Jack et al., 2016). Such work is only just beginning to impact
upon a potential redefinition of AD diagnostic boundaries.
2.2. Schizophrenia
Descriptions of the schizophrenic syndrome have been prevalent in
the scientific literature for more than a century (Fox, 1978; Hoenig,
1983; Snowden, 2009). Notably, the term dementia praecox (“premature
dementia”) has been historically used to describe the disease (Noll,
2011). Schizophrenia is a relatively non-progressive neuropsychiatric
disorder characterised and diagnosed by a constellation of symptoms
(American Psychiatric Association, 2018). A classic presentation would
be a teenager or young adult exhibiting signs of prodromal psychosis-
like behaviour (e.g., unusual thoughts, perceptual abnormalities, social
withdrawal) that may lead to “first break”, i.e., a full-blown episode of
psychosis requiring medical intervention (Birchwood et al., 1998; Kahn
and Sommer, 2015). The prognosis of such patients will vary depending
on responsiveness to treatment and other symptoms that may subse-
quently emerge (Alvarez-Jimenez et al., 2016; Diaz-Caneja et al., 2015;
Millan et al., 2016; Zhu et al., 2017a, b). Patients often have little in-
sight into their illness (Amador et al., 1994; Pousa et al., 2017).
Schizophrenia is currently diagnosed solely on the expression of
subjectively interpreted symptoms (American Psychiatric Association,
2018; Kahn et al., 2015; World Health Organization, 1992), where a host
of different factors can inform diagnosis. “Positive” psychotic elements,
such as delusions and hallucinations, likely bring a patient to the at-
tention of the healthcare system, and existing antipsychotics can fairly
successfully moderate these symptoms (Leucht et al., 2009, 2017).
However, the schizophrenic syndrome is also composed of “negative”
and “cognitive” elements (Kay, 1990; McGlashan and Fenton, 1992;
Tandon et al., 2009), that may ultimately be more damaging to the long-
term health outlook of the patient (Aleman et al., 2017; Green, 1996;
Patel et al., 2015). Negative symptoms refer to a reduction from a
baseline functional capacity, such as apathy, flat affect, and isolation/
social withdrawal (Kirkpatrick et al., 2006; Winograd-Gurvich et al.,
2006). Cognitive symptoms encompass symptoms defined more precisely
by their neuropsychological nature. Several recent collaborative efforts
have attempted to systematise and formalise neuropsychiatric research in
this area, such as the National Institute of Mental Health-sponsored
MATRICS (Measurement and Treatment Research to Improve Cognition
in Schizophrenia) and CNTRICS (Cognitive Neuroscience Treatment Re-
search to Improve Cognition in Schizophrenia) initiatives. These efforts
have moved away from the symptom cluster approach and posited a
more precise cognitive framework in which to study the schizophrenic
syndrome (Carter and Barch, 2007; Kern et al., 2008; Marder, 2006;
Marder and Fenton, 2004; Nuechterlein et al., 2008). In comparison to
the AD field, schizophrenia research has made significant progress in
attempting to deconstruct the disease into more quantitative neu-
ropsychological endpoints, although the syndrome itself does not have
any robust neuropathological hallmarks or pathological biomarkers of
diagnostic utility (Scarr et al., 2015).
2.3. Overlapping symptoms in Alzheimer’s disease and schizophrenia
Potential commonalities between AD and schizophrenia are most
apparent when considering the presentation of NPS. In AD, NPS are
highly prevalent and considered to accelerate disease progression and
interfere with treatment effects to worsen prognosis for those afflicted
(Barton et al., 2016; Finkel et al., 1996; Lyketsos et al., 2011; Steffens
et al., 2009). It has been estimated that more than 80% of probable AD
patients will also exhibit at least one NPS (Lyketsos et al., 2002). The
most widely used measure of NPS in AD research is the Neu-
ropsychiatric Inventory (Cummings et al., 1994), which assesses several
domains of behavioural functioning, including delusions, hallucina-
tions, agitation/aggression, dysphoria, anxiety, euphoria, apathy, dis-
inhibition, irritability/lability, aberrant motor activity, nocturnal dis-
turbance and eating abnormalities (Cummings, 1997). A recent meta-
analysis underscored apathy as the most prevalent NPS in AD, also
associated with the severest cognitive impairment (Zhao et al., 2016).
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Other prevalent NPS in AD include depression, aggression, anxiety and
sleep disturbance. The aggregated prevalence of sleep disturbance in
AD patients has been estimated to be 39% in a recent meta-analysis
including data from 48 studies (Table 1) but there is heterogeneity
across studies, perhaps related to variation on disease duration, se-
verity, age, medication, etc., and the tools used to assess sleep dis-
turbance (Carpenter et al., 1996; McCurry et al., 2000; Rebok et al.,
1991; Zhao et al., 2016). In schizophrenia, psychosis and negative
symptoms are defining features of the disease. In addition, complaints
of sleep disturbance are a very common prodromal symptom preceding
the first psychotic episode for most schizophrenic patients (Tan and
Ang, 2001; Yung and McGorry, 1996; Zanini et al., 2013). Thereafter,
depending on illness duration and disease severity, many patients will
continue to exhibit sleep disturbance (Chan et al., 2017).
It might not be unreasonable therefore to assume that apathy in AD
may share overlapping features with negative symptoms in schizo-
phrenia (Chase, 2011; Weiser and Garibaldi, 2015), as might aspects of
psychosis and sleep disturbance share common biology between each
disease. However, there are significant shortcomings from published
studies to be able to make strong conclusions about these relationships at
present, and certainly not enough data to be able to redefine diagnostic
boundaries of either disease. Taking sleep disturbance as an example, this
review will focus on this issue, highlighting technical issues to overcome,
describing what is known about commonalities in sleep disturbance be-
tween each disease, and suggesting what future work might need to be
done in an attempt to redefine the boundaries of these diseases.
3. Assessment of sleep and circadian rhythmicity
3.1. Methodology
Sleep has several dimensions and can be quantified in many different
ways (Fig. 1). Appropriate parsing of these dimensions will inform the
discussion about the nature of sleep disturbance in psychiatric and neu-
rological disorders. Sleep exists as 1) a subjective experience, i.e., sub-
jective sleep quality, sleep sufficiency, sleepiness; 2) as an observed be-
haviour, e.g., the restlessness or night wandering noted by the bed partner
or caregiver; 3) as an objectively assessed behaviour, e.g., by actigraphy
or polysomnography (PSG); 4) as an expression of circadian organisation.
The subjective experience of sleep can be assessed by sleep diaries
and questionnaires such as the consensus sleep diary (Carney et al.,
2012), the Karolinska sleep diary (Åkerstedt et al., 1994), the Karolinska
Sleepiness Scale (Åkerstedt and Gillberg, 1990), the Epworth Sleepiness
Scale (Johns, 1991), and the widely used Pittsburgh Sleep Quality In-
ventory (Buysse et al., 1989), amongst others. These tools provide in-
formation on the subjective quality of sleep and sleepiness, as well as the
timing and duration of sleep. However, they have not been developed in
the context of psychiatric and neurological disorders and therefore may
not be appropriate for all patients in this context. In fact, in many studies
of sleep disturbance in patient populations and AD in particular, "custom
made" tools or informal assessments are used (Table 1). Whereas these
custom approaches may capture relevant aspects of the specific disease,
they do not facilitate comparison across studies and conditions. Inter-
views with carers and/or partners can provide insight into both the sleep
of the patient, as well as the impact of the sleep of the patient on the
carer, an aspect that recently has received more attention.
Objective quantification of nocturnal sleep can be obtained through
actigraphy or PSG. Actigraphy measures rest and activity, and acti-
graphy of nocturnal sleep has shown reasonable concordance with PSG
for the classification of wakefulness vs. sleep in healthy controls and
insomnia patients (Marino et al., 2013). However, accuracy of this
sleep-wake classification has not been assessed in AD and schizo-
phrenia. Furthermore, many new actigraphy based devices entering the
market have not been validated at all. Actigraphy cannot quantify
stages of sleep such as rapid-eye movement (REM) sleep, non-rapid-eye
movement (NREM), sub-stages of Slow Wave Sleep (SWS), and specificTa
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electroencephalographic (EEG) phenomena such as slow waves and
sleep spindles. These brain states and phenomena can only be quanti-
fied by PSG recording (Box 1). In practice, three variables are con-
sidered in PSG assessments of sleep: these are the EEG, electro-
oculogram and electromyogram. Combinations of these variables define
the states of waking, NREM sleep and REM sleep.
Quantitative analysis of EEG (e.g. spectral analysis, wavelet ana-
lysis, non-linear approaches), can provide further information on
changes in sleep and wakefulness associated with specific conditions.
Addition of sensors to assess breathing movements, airflow, limb
movements and heart rate are used to assess specific sleep disorders
such as obstructive and central sleep apnoea, and periodic limb
movements. Video recordings may be used to assess abnormal move-
ments and REM sleep behaviour disorder. Whereas sleep has long been
viewed as a global brain state, more recently attention has been drawn
to local aspects of sleep. The essence of this "local view” of sleep is that
during wakefulness particular brain circuits may be in a sleep-like state
and during sleep some areas may be more or less asleep than other
areas (Andrillon et al., 2011; Nir et al., 2017; Siclari and Tononi, 2017;
Siegel, 2001). High density EEG allows assessment of topographical/
local changes and can also be used to assess network properties such as
coherence and global field synchronisation. Application of high density
EEG has rarely been used in the context of sleep research in psychiatric
and neurological disorders and obviously is difficult to implement in
the home environment, but nevertheless holds promise for furthering
our understanding of changes in sleep (DʼAgostino et al., 2018). Several
recent developments such as new electrode designs, miniaturisation of
EEG amplifier and data storage technology, signal analysis and machine
learning approaches which can identify sleep stages from fewer elec-
trodes/variables, have led to the prospect of long-term EEG based sleep
monitoring in real life settings (Debener et al., 2015; Pillay et al., 2018).
Whereas the approaches discussed so far emphasize assessment of
the major nocturnal sleep episode, they do not necessarily focus on the
timing of sleep, which may include broken nocturnal sleep and daytime
Fig. 1. Subjective and objective assessments of sleep in patient populations. Sleep has many dimensions and various tools and approaches are used to capture
these dimensions. Subjective assessments provided by patients and/or partners/caregivers via interviews and/or using customised questionnaires have highlighted
differences in perception between patients and caregivers. While these tools allow the evaluation of several aspects of sleep (e.g., sleep quality, duration, daytime
sleep and sleepiness), they do not facilitate comparison across studies and disorders as they are often tailored for specific psychiatric or neurological patient
populations. Objective assessments are primarily based on actigraphy and polysomnography. Actigraphy allows the capture of 24-h rest-activity rhythms on a long-
term basis and in a home-based environment. Polysomnography (electroencephalogram/electrooculogram/electromyogram) is still primarily performed in a la-
boratory/clinical research environment. It can distinguish between vigilance states (waking, NREM and REM sleep), quantify them, and also with quantitative EEG
analysis can evaluate EEG hallmarks reflecting changes in brain activity and underlying mechanisms. EEG: electroencephalogram; EMG: electromyogram; EOG:
electrooculogram.
Box 1
Vigilance states (●) and characteristic EEG hallmarks (○) in humans.
• Wakefulness
○ Active wake: beta rhythms (> 14Hz)
○ Quiet resting state: alpha rhythms (8–12 Hz)
○ Drowsiness: theta rhythms (4–7 Hz)• NREM sleep is subdivided in 3 stages (N1-3):• N1: theta rhythms (4–7 Hz)• N2: K-complexes, spindles (12–15Hz)• N3 (also known as deep SWS): slow waves (delta rhythms 0.5–4.5 Hz))• REM sleep (also known as paradoxical sleep)• Theta, alpha and beta rhythms (> 14 Hz)
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naps within the 24-h cycle. Longitudinal continuous assessment of ac-
tivity through actigraphy can provide a quantification of the circadian
organisation of sleep. Detailed analysis of circadian rhythmicity may
require collection of time series of physiological markers such as core
body temperature, melatonin and cortisol although implementation of
the required methodology in a home and patient setting is obviously
challenging. Quantification of circadian organisation through a new
generation of wearables collecting multiple variables holds promise (Li
et al., 2017; Walch et al., 2016) although validation of the devices and
algorithms to quantify circadian organisation is often lacking.
3.2. Relevance of different sleep measures
Within the general population, the subjective experience of sleep
and its disturbance is one of the most significant determinants of quality
of life (Strine and Chapman, 2005). Always feeling tired, or excessive
daytime sleepiness, is a common complaint and often a consequence of
insufficient or disrupted sleep (Hasler et al., 2005). Complaints of poor
sleep quality and excessive sleepiness are associated with cognitive
decline (Blackwell et al., 2014; Jaussent et al., 2012; Waller et al.,
2016). Subjective quality of sleep is associated with the consolidation of
sleep, i.e., the inverse of the number of sleep interruptions and wake
after sleep onset occurrences, and REM sleep (Della Monica et al., 2018;
Kaplan et al., 2017). Thus, poor subjective sleep quality and excessive
daytime sleepiness are sensitive and early indicators of sleep disruption.
Nocturnal sleep timing in healthy adults is regular, with a 7–8 h sleep
duration being considered optimal (Consensus Conference Panel et al.,
2015). Both self-reported short (<6 h) and long sleep durations (>9 h)
are associated with negative health outcomes (Matricciani et al., 2017;
Westwood et al., 2017; Suh et al., 2018) and cognitive decline (Lo et al.,
2016). In healthy adults, sleep generally occurs as one consolidated night-
time bout, with sustained wakefulness and alertness throughout the day,
although occasional short daytime naps are not considered abnormal
(Leng et al., 2017). Indeed, self-reported excessive daytime sleepiness,
napping, and in particular long naps may be predictive of cognitive de-
cline (Cross et al., 2015). Thus, subjective reports of abnormal sleep
duration and timing and sleepiness provide relevant information.
PSG-based quantifications of sleep are usually based on summary
statistics for variables such as Total Sleep Time (TST), NREM sleep time,
N1, N2, N3 (SWS), REM sleep time, Wake After Sleep Onset, Number of
Awakenings, Latency to Sleep and Latency to REM sleep. Alterations in
these variables may reflect changes in brain circuits and neuromodulatory
systems implicated in the generation of sleep and its substrates. Sleep is
also associated with changes in cerebral blood flow, skeletal muscle tone,
respiratory, cardiovascular, metabolic and endocrine variables, con-
sciousness and mentation. Beneficial effects of healthy sleep or negative
effects of disrupted sleep may be related to any of these variables. The
value of assessing EEG activities is often related to their suspected con-
tribution to brain function and in particular their roles in learning,
memory and mood regulation. It seems fair, however, to state that cur-
rently the specific contribution of and the mechanism by which the var-
ious sleep stages, sleep continuity, sleep duration, specific sleep oscilla-
tions etc., to brain health has not been established (Boyce et al., 2017; Feld
and Born, 2017; King et al., 2017). Nevertheless, PSG assessment of sleep
provides a comprehensive window on brain state and other physiological
functions and may provide new biomarkers for cognitive decline.
Disturbances of sleep timing, duration and structure may also be in-
dicators of disrupted circadian rhythmicity. Long-term recordings of rest-
activity cycles via actigraphy (Morgenthaler et al., 2007) or sleep diaries
can be particularly informative about the extent of sleep duration and
timing disturbances (e.g., extreme late or early sleep, extreme short or
long sleep, excessive daytime napping) which may reflect disrupted cir-
cadian regulation of sleep. Assessment of circadian rhythmicity through
markers such as the daily pattern of mood disturbances, agitation, or
physiological markers such as melatonin (Magri et al., 2004), cortisol,
orexin (Liguori, 2017), or the rhythmic expression of clock genes (Lim
et al., 2017) can provide information about the patency of temporal or-
ganisation. Assessment of circadian rhythmicity may be informative since
its disruption can be predictive of cognitive decline (Zelinski et al., 2014).
Specific methods of assessing sleep and circadian parameters have
their strengths and weaknesses. For example, while PSG assessments of
sleep in the sleep laboratory will provide detailed information on sleep
structure, sleep continuity and EEG phenomena, it will not provide a
reliable estimate of sleep patterns and TST per 24-h. This is a simple
consequence of laboratory recording times being constrained.
Actigraphy allows for assessment of these parameters in the real world
environment although it should be kept in mind that even in the real
world, rest-activity cycles may to some extent reflect imposed social
schedules (e.g., in care homes) rather than the self-selected sleep
schedule of the patient.
3.3. Measuring sleep parameters in the context of sleep disorders
So far, discussion of sleep and circadian parameters has been ap-
proached from a basic sleep phenomenology perspective, without spe-
cific reference to clinical sleep and circadian disorders. The
International Classification of Sleep Disorders recognises six major
sleep disorders. These are Insomnia, Sleep-Related Breathing Disorders,
Central Disorders of Hypersomnolence, Circadian Rhythm Sleep-Wake
Disorders, Parasomnias, and Sleep Related Movement Disorders
(American Academy of Sleep Medicine, 2014). In the DSM5, eleven
sleep disorders are listed (Box 2).
Box 2
Sleep disorders listed in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
• Insomnia disorder• Hypersomnolence disorder• Narcolepsy• Obstructive sleep apnoea/hypopnea• Central sleep apnoea• Sleep-related hypoventilation• Circadian rhythm sleep-wake disorders• Non-rapid eye movement (NREM) sleep arousal disorders• Nightmare disorder• Rapid eye movement (REM) sleep behavior disorder• Restless legs syndrome and substance-/medication-induced sleep disorder
Reference: American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC:
American Psychiatric Association, 2013.
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Sleep disturbances and sleep disorders are common in mental dis-
orders but are also co-morbid in many other conditions (e.g., cancer,
multiple sclerosis, diabetes). Diagnostic criteria for sleep disorders do
not necessarily include important physiological aspects of sleep such as
the duration of SWS, REM sleep, number of sleep spindles and number
of awakenings. Understanding of the contribution of sleep to brain
function and pathophysiology will benefit from both an assessment of
sleep disorders as well as sleep-physiology/phenomenology.
4. Sleep and circadian disturbance in Alzheimer’s disease and
schizophrenia
Here, a series of studies on sleep and circadian disturbance in AD
and schizophrenia have been compiled (Tables 1–4). Description and
interpretation of sleep and circadian disturbance in patient populations
is complicated by variation in disease severity, medication status and
specificity and sensitivity of the tools used to quantify these dis-
turbances. Thus, where data has been provided, these factors are spe-
cifically noted. The included clinical and preclinical studies were
identified through a PUBMED search with the following search terms:
“Alzheimer’s disease+ sleep”; “schizophrenia+ sleep”; “Alzheimer’s
disease+ circadian”; “schizophrenia+ circadian”, as well as searches
related to specific sleep parameters: e.g. “sleep spindles+
schizophrenia” and “REM+Alzheimer’s disease”. Articles were se-
lected based on comprehensiveness, recency and accessibility.
4.1. Sleep in Alzheimer’s disease
4.1.1. Subjective assessments
Subjective assessments of sleep in AD are often obtained through
interviews with patients or caregivers (Table 1). AD patients may not
always have insight into their potential problems with sleep dis-
turbance. For example, it has been reported that the perception by AD
patients of their sleep quality is rather positive, with a large proportion
of patients (83–91%) reporting their sleep as satisfactory (Ancoli-Israel
et al., 1994; de Oliveira et al., 2014). However, complaints of sleep
disruption, difficulty falling asleep and night awakenings are also fre-
quently reported, with prevalence ranging from 11 to 45%. How ab-
normal these prevalence estimates are is difficult to assess because in
most studies an aged-matched control group was not included. Daytime
sleep (i.e., napping) and sleep timing disturbances are also frequently
reported. Overall, caregiver report analyses suggest an increased
number of nocturnal awakenings and early morning awakenings, ab-
normal diurnal sleep-wake patterns, and excessive daytime sleepiness
and napping (Carpenter et al., 1996; McCurry et al., 1999; Peter-Derex
et al., 2015; Rebok et al., 1991). To what extent this subjective sleep
disturbance is a consequence of medication for AD, has a lower or
higher than expected prevalence because of the use of sleep medication,
cannot be reliably assessed from the existing literature.
4.1.2. Objective assessments
In studies in which subjective and objective assessments were ob-
tained simultaneously, discrepancies between subjective reports of pa-
tients and objective measures of sleep by actigraphy become apparent
even in the early stages of the disease (Most et al., 2012). In the
broadest sense, however, objective assessments of AD patients confirm
that sleep is disrupted (Table 2). There is a general consensus from
published actigraphy studies that AD patients experience a reduction in
sleep efficiency and a higher number of awakenings. Estimates of
changes in TST in AD are less consistent however, with some studies
reporting reductions in TST, whilst others do not (Lauriola et al., 2017;
Leger et al., 2017; Most et al., 2012; Musiek et al., 2018; Tanev et al.,
2017; Weissova et al., 2016). In a recent study using actigraphy in a
carefully controlled group of patients with moderate AD, excluding a
number of confounding factors (e.g., mixed diagnosis, comorbidities,
pharmacological treatments), patients time in bed and TST were longer
in AD (Wams et al., 2017). All of these studies may however potentially
be compromised by the unconfirmed validity of actigraphy for assess-
ment of sleep in AD. PSG studies have confirmed an increase in the
number of awakenings and in general report a reduction in TST. As
mentioned, laboratory assessment of TST may not reflect TST in the
home environment because recording periods are often limited to a
conventional 8-hour nocturnal sleep period. PSG studies have shown
that SWS and EEG Slow Wave Activity (SWA) is either unchanged or
reduced in AD (Table 2), while a recent study highlighted an associa-
tion between carrying the apolipoprotein E ε4 allele and an increased
N3 duration in the elderly (Tranah et al., 2018). Sleep spindles are
sometimes reported to be reduced in AD (Feinberg et al., 1967;
Montplaisir et al., 1995; Reynolds et al., 1985; reviewed in Peter-Derex
et al., 2015; Petit et al., 2004; Villa et al., 2015) although not assessed
in many studies. Alterations in REM sleep parameters are frequently
identified in AD. REM sleep duration or REM sleep percentages are
generally reported as being decreased in AD, including medication-free
patients, although in some studies REM was unchanged (Bliwise, 1993;
Loewenstein et al., 1982; Vitiello et al., 1984). Reports on changes in
REM sleep latency are more variable, with some studies reporting an
increase in latency to REM sleep, whilst others report no significant
changes or a decrease (Bliwise, 1993; Bliwise et al., 1989; Loewenstein
et al., 1982; Montplaisir et al., 1995; Prinz et al., 1982a, b; Reynolds
et al., 1985).
Changes in SWS and SWA in NREM sleep have received much at-
tention. For example, in older adults, SWA was shown to be related to
grey matter atrophy in medial prefrontal cortex and to mediate im-
pairment in sleep-dependent memory (Mander et al., 2013). In a sub-
sequent study it was shown that reductions in SWA were correlated
with β-amyloid burden (Mander et al., 2015). Based on these and other
data changes in SWS and SWA were recently proposed to be a pro-
mising biomarker for early diagnosis of AD (Mander et al., 2016).
Changes in EEG frequencies in other vigilance states have been con-
sidered in the context of AD as well. For example, EEG theta activity
appears to be increased in AD patients in particular during REM sleep
(Hassainia et al., 1997; Horvath et al., 2018). A longitudinal study in
the mild stage of AD reported that theta activity in resting EEG during
wakefulness was the first parameter, and delta activity the last, to show
alterations (Coben et al., 1985). In this context it may be mentioned
that several studies have described the presence of a diffuse, overall
EEG slowing during wakefulness, observable even in early stages of AD
(Horvath et al., 2018; Montplaisir et al., 1995; Peter-Derex et al., 2015;
Petit et al., 2004; Prinz and Vitiello, 1989). There are also more specific
reports of theta activity increases and alpha activity decreases in
waking EEG power in AD patients (Bliwise, 1993; Horvath et al., 2018).
EEG slowing in general refers to an increased dominance of low fre-
quency oscillations, which may reflect a shift from alpha activity to
theta and delta activity. Such a slowing may reflect either an increase in
the amplitude of low frequency oscillations or a change in the fre-
quency domain. While such EEG slowing phenomena may potentially
be a sensitive marker of global changes in brain function/network in-
tegrity independent of vigilance state in AD patients, they may also
make it more difficult to discriminate between vigilance stages in more
formal sleep studies. Alternatively, these data may suggest that from an
EEG perspective, the difference between waking and sleep states be-
comes less distinguished in AD.
4.1.3. Circadian alterations
Sleep diary and actigraphy studies have shown that sleep timing can
be altered in AD, albeit with a great variability between patients that
may relate to disease severity (Hatfield et al., 2004; Weissova et al.,
2016). Delayed wake time has been shown to be associated with higher
dementia risk (Bokenberger et al., 2017). Another indicator of altered
circadian rhythmicity in AD patients is the deterioration of daily sleep-
wake pattern consolidation, with some patients exhibiting higher noc-
turnal and lower diurnal activities than normal. These changes can be
R. Winsky-Sommerer et al. Neuroscience and Biobehavioral Reviews 97 (2019) 112–137
118
Ta
bl
e2
Pr
ev
ale
nc
eo
fO
bje
cti
ve
Sle
ep
Di
stu
rb
an
ce
in
Pa
tie
nt
sw
ith
Al
zh
eim
er'
sd
ise
as
e.
AL
ZH
EI
ME
R'S
DI
SE
AS
E
Re
fer
en
ce
Sa
mp
le
Siz
e
Ag
eM
ea
n/
Ra
ng
e
Se
ve
rit
y
Tr
ea
tm
en
t
Ty
pe
of
Sle
ep
As
ses
sm
en
t
To
tal
Sle
ep
Ti
me
Sle
ep
du
rat
ion
:
NR
EM
Sta
ge
1
Sle
ep
du
rat
ion
:
NR
EM
Sta
ge
2
Sle
ep
du
rat
ion
:
NR
EM
Sta
ge
3/
4
or
SW
S
Sle
ep
du
rat
ion
:
RE
M
sle
ep
Al
len
et
al.
,1
98
7
30
>
80
Se
ve
re
No
me
dic
ati
on
at
th
et
im
eo
ft
he
stu
dy
or
for
at
lea
st
5-w
ee
ks
pr
ior
to
th
e
stu
dy
.
PS
G
↓
→
↓
→
↓
Bl
iw
ise
et
al.
,1
98
9
28
67
.6
(±
8.6
5)
Mi
ld
to
Mo
de
rat
e
No
me
dic
ati
on
at
th
et
im
eo
ft
he
stu
dy
or
for
at
lea
st
1-w
ee
kp
rio
rt
ot
he
stu
dy
.
PS
G
→
↑
→
↓
→
Fe
inb
erg
et
al.
,1
96
7
15
64
-9
2
No
tA
sse
sse
d
No
tra
nq
uil
izi
ng
or
sed
ati
ve
dr
ug
s
du
rin
gt
he
pr
ev
iou
s3
we
ek
s.
PS
G
↓
–
–
↓
↓
Ha
ssa
ini
ae
ta
l.,
19
97
27
57
-7
6
Mi
ld
to
Mo
de
rat
e
No
me
dic
ati
on
for
at
lea
st
2w
ee
ks
pr
ior
to
th
es
tu
dy
.
PS
G
–
–
–
–
–
La
ur
iol
ae
ta
l.,
20
17
70
64
.8
(±
6.3
)
Pr
ec
lin
ica
l
No
sle
ep
or
ps
yc
ho
tro
pic
me
dic
ati
on
Ac
tig
rap
hy
→
–
–
–
–
Le
ge
re
ta
l.,
20
17
20
8
≥
50
Mi
ld
to
Mo
de
rat
e
No
tR
ep
ort
ed
Ac
tig
rap
hy
→
–
–
–
–
Lig
uo
ri
et
al.
,2
01
4
48
70
.5
(±
7.6
)
Mi
ld
to
Se
ve
re
Dr
ug
-na
ïve
AD
pa
tie
nt
s
PS
G
–
↑
–
↓
↓
Lo
ew
en
ste
in
et
al.
,1
98
2
9
52
-7
0
Mi
ld
to
Mo
de
rat
e
No
me
dic
ati
on
at
th
et
im
eo
ft
he
stu
dy
.
PS
G
→
→
→
→
→
Mo
nt
pla
isi
re
ta
l.,
19
95
10
60
.6
Mi
ld
to
Mo
de
rat
e
No
tR
ep
ort
ed
PS
G
→
↑
→
→
↓
Mo
st
et
al.
,2
01
2
55
70
.4
(±
3.2
)
Mo
de
rat
e
β-
blo
ck
ers
,c
ho
lin
est
era
se
inh
ibi
tor
s,
sle
ep
me
dic
ati
on
,a
nt
ide
pr
ess
an
ts,
an
tip
sy
ch
oti
cs
Ac
tig
rap
hy
→
–
–
–
–
Mu
sie
ke
ta
l.,
20
18
18
9
66
.6
(±
8.3
)
Pr
ec
lin
ica
l
No
tR
ep
ort
ed
Ac
tig
rap
hy
–
–
–
–
–
Pr
inz
et
al.
,1
98
2a
10
58
-8
8
Se
ve
re
No
ps
yc
ho
tro
pic
me
dic
ati
on
for
at
lea
st
1m
on
th
pr
ior
to
th
es
tu
dy
.
PS
G
↓
–
–
↓
↓
Pr
inz
et
al.
,1
98
2b
44
67
.8
(±
9.4
6)
-
72
.8
(±
10
.97
)
Mi
ld
to
Se
ve
re
No
ps
yc
ho
tro
pic
me
dic
ati
on
for
at
lea
st
1m
on
th
pr
ior
to
th
es
tu
dy
.
PS
G
↓
–
–
↓
↓
Re
yn
old
se
ta
l.,
19
85
25
70
.4
(±
8.3
)
Mi
ld
No
me
dic
ati
on
for
at
lea
st
2w
ee
ks
pr
ior
to
th
es
tu
dy
.
PS
G
↓
↑
↓
→
↓
Re
yn
old
se
ta
l.,
19
88
49
72
.8
(±
8.0
)
Mo
de
rat
et
oS
ev
ere
No
ps
yc
ho
tro
pic
me
dic
ati
on
for
at
lea
st
2w
ee
ks
pr
ior
to
th
es
tu
dy
.
PS
G
↓
–
–
–
↓
Ta
ne
ve
ta
l.,
20
18
28
81
.61
(±
9.3
)
Mi
ld
to
Se
ve
re
An
tid
em
en
tia
dr
ug
s
Ac
tig
rap
hy
→
–
–
–
–
Vi
tie
llo
et
al.
,1
99
0
44
70
.7
(±
7.5
)
Mi
ld
No
ps
yc
ho
ac
tiv
em
ed
ica
tio
nf
or
at
lea
st
2w
ee
ks
pr
ior
to
th
es
tu
dy
.
PS
G
→
→
→
–
→
W
am
se
ta
l.,
20
17
29
77
.1
(±
4.0
)-
77
.7
(±
7.6
)
Mi
ld
to
Mo
de
rat
e
No
ps
yc
ho
ac
tiv
em
ed
ica
tio
nf
or
at
lea
st
2w
ee
ks
pr
ior
to
th
es
tu
dy
.
Ac
tig
rap
hy
↑
–
–
–
–
W
eis
so
va
et
al.
,2
01
6
13
78
.9
(±
1.9
)
Mi
ld
An
tid
em
en
tia
dr
ug
s(
e.g
.
ac
ety
lch
oli
ne
ste
ras
ei
nh
ibi
tor
s)
bu
tn
o
sle
ep
me
dic
ati
on
Ac
tig
rap
hy
→
–
–
–
–
AL
ZH
EI
ME
R'S
DI
SE
AS
E
Re
fer
en
ce
Sle
ep
Effi
cie
nc
y
Sle
ep
La
ten
cy
Nu
mb
er
of
Ni
gh
t
Aw
ak
en
ing
s
EE
G
SW
A/
De
lta
EE
G
Sle
ep
Sp
ind
les
EE
G
RE
M
La
ten
cy
EE
G
Di
ffu
se
Slo
wi
ng
Da
yti
me
Sle
ep
Ne
ur
op
sy
ch
iat
ri-
cA
sse
ssm
en
t
Co
rre
lat
ion
wi
th
Sle
ep
Al
len
et
al.
,1
98
7
–
–
–
–
–
–
–
–
N/
A
N/
A
Bl
iw
ise
et
al.
,1
98
9
↓
–
–
–
–
↑
–
–
N/
A
N/
A
Fe
inb
erg
et
al.
,1
96
7
–
–
↑
↓
↓
–
–
–
N/
A
N/
A
Ha
ssa
ini
ae
ta
l.,
19
97
–
–
–
–
–
–
Pr
ese
nt
–
N/
A
N/
A
La
ur
iol
ae
ta
l.,
20
17
↓
↑
↑
–
–
–
–
–
De
pr
ess
ion
✗
Le
ge
re
ta
l.,
20
17
→
–
↑
–
–
–
–
–
Ap
ath
y
✓
Lig
uo
ri
et
al.
,2
01
4
↓
–
–
–
–
↑
–
–
N/
A
N/
A
R. Winsky-Sommerer et al. Neuroscience and Biobehavioral Reviews 97 (2019) 112–137
119
interpreted as a reduction in the strength or amplitude of circadian
rhythmicity (Hatfield et al., 2004; Satlin et al., 1995; Wams et al.,
2017). It is thought that neurodegeneration in the suprachiasmatic
nucleus, the circadian master clock, and alterations in melatonin levels
contribute to circadian alterations in AD (Ferrari et al., 2000; Harper
et al., 2008; Wu et al., 2003). However, reduced or altered plasma
melatonin profiles and circadian rest-activity patterns have not been
observed in all studies (Weissova et al., 2016). Cerebrospinal fluid
(CSF) melatonin levels were found to be reduced in preclinical stages of
AD, exhibiting a gradual decline with the course of AD neuropathology
(Wu et al., 2003), while cortisol rhythms seemed to remain relatively
unchanged (Hatfield et al., 2004). Some papers report that in severe
cases of AD, a “sundowning” syndrome, described as a nocturnal wor-
sening of some neuropsychiatric symptoms such as agitation, may be
observed (for review, Bachman and Rabins, 2006; Bliwise, 1993;
Iranzo, 2016; Peter-Derex et al., 2015). However, due to the loose de-
finition used across studies (Bliwise, 1993), it is difficult to assess its
prevalence. A carefully conducted study of the temporal distribution of
agitation suggested that the sundowning syndrome may merely reflect a
change of perception from caregivers, rather than an actual exacerba-
tion of behavioural disruption near sunset or at night (Bliwise et al.,
1993).
4.1.4. Other sleep disorders
Obstructive sleep apnoea (OSA) has been studied extensively in the
context of AD and is suggested to be a predictor of disease development
(Hita-Yanez et al., 2012; Polsek et al., 2018; Shi et al., 2017a,b; Liguori
et al., 2017). OSA is characterised by an intermittent cycle of repetitive
pauses in breathing with associated hypoxia, which leads to numerous
night-time arousals, and consequently, sleep fragmentation. OSA may
cause or exacerbate excessive daytime sleepiness (Wennberg et al.,
2017) and daytime napping in AD and may lead to sleep timing changes
that may present as alterations in circadian organisation (Weissova
et al., 2016; Zeitzer et al., 2013). OSA has been recognised as a po-
tential risk factor for AD (Sharma et al., 2018; Yaffe et al., 2011). The
prevalence of OSA has been reported to be as high as 70% in AD
(Ancoli-Israel et al., 1991; Gehrman et al., 2003). Individuals with AD
have a five times higher risk of OSA than healthy controls (Emamian
et al., 2016), with OSA preceding cognitive decline usually by a decade
(Sharma et al., 2018). Treating OSA patients with continuous positive
airway pressure reduces the onset or progression of mild cognitive
impairment (MCI) (Sharma et al., 2018), and may even attenuate the
cognitive decline generally associated with mild to moderate AD
(Troussiere et al., 2014). However, the potential of using OSA as a
predictive diagnostic and/or therapeutic target in AD has yet to be fully
explored. In contrast to OSA, Periodic Limb Movements during Sleep
(PLMS) is another sleep disorder with a high prevalence in older adults
(Gehrman et al., 2002); however, its prevalence appears not to be in-
creased in AD (Bliwise et al., 2012).
Overall, changes in sleep fragmentation, REM and SWS in AD may
be secondary to sleep disordered breathing or periodic limb move-
ments. Likewise, excessive daytime sleepiness and lower cognitive
status, as assessed by the Mini Mental State Examination (Lee et al.,
2007; Merlino et al., 2010; Rebok et al., 1991) in AD may be caused by
sleep disorders.
4.1.5. Effects of AD medications on sleep
While pharmacological treatments for AD are currently very lim-
ited, these treatments affect neurotransmitter systems involved in sleep-
wake regulation and thereby are likely to have an impact on sleep in AD
patients (Scammell et al., 2017). Pharmacological treatments for AD
include both acetylcholinesterase inhibitors and memantine, a non-
competitive NMDA receptor antagonist (Deardorff et al., 2015; Epperly
et al., 2017; Herrmann et al., 2011). Both treatments offer some
symptomatic relief for a period but ultimately do not halt progression of
the disease (Birks, 2006; Ehret and Chamberlin, 2015; McShane et al.,Ta
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2006). PSG-based studies with anticholinesterase inhibitors, such as
donepezil, document an increase in REM sleep percentage and reduced
REM sleep latency that may effectively normalise REM sleep parameters
in AD patients (Peter-Derex et al., 2015; Schweitzer and Randazzo,
2016).
4.1.6. Effects of sleep medications in AD
A review of pharmacological treatments of sleep disturbance in AD
(McCleery et al., 2016) highlighted that very few studies are available
to provide guidance. The antidepressant trazodone may improve TST in
moderate to severe AD patients, although no beneficial effect on sleep
fragmentation was observed. Available evidence does not support the
use of drugs acting at melatonin receptors (i.e., melatonin, ramelteon)
for the treatment of sleep disturbance in AD (McCleery et al., 2016). It
is currently not known whether the dual orexin antagonists are effective
in treating sleep disturbances in AD.
4.2. Sleep in Schizophrenia
4.2.1. Subjective assessments
The prevalence of sleep complaints is very high in schizophrenia
patients (Table 3). Subjective assessments of sleep in schizophrenic
patients revealed difficulty in falling asleep, numerous night-time
awakenings, and daytime napping (Poulin et al., 2010). Furthermore,
sleep duration is highly variable, ranging between 3–14.5 hours
(median 8 h) in a self-report study (Faulkner & Bee, 2017). An in-depth
interview study of how sleep was experienced, valued and perceived by
schizophrenia patients revealed that "changes to sleep were interpreted
as part of a perceived loss of normality relating to diagnosis". This
analysis also indicated that sleep sometimes was experienced as an
opportunity to escape (Faulkner and Bee, 2017), which may relate to
the very long sleep periods often observed. According to patient and
family member reports, sleep disturbance such as disruption of sleep
continuity is highly prevalent before the first episode of psychosis, and
insomnia symptoms tend to intensify before relapse (Benson, 2015;
Eisner et al., 2013).
4.2.2. Objective assessments
Consistent with subjective assessments, most PSG nocturnal sleep
studies report an increased sleep latency, higher number of awakenings,
decreased TST and lower sleep efficiency in schizophrenia compared to
healthy controls (Chan et al., 2017; Chouinard et al., 2004) (Table 4).
Any discrepancies between subjective and objective assessments of
sleep duration in schizophrenia may, as in AD, potentially be an artefact
of the scheduling of PSG-based laboratory assessment. Alterations in
SWS and REM sleep durations, as well as REM sleep latency, are rela-
tively inconsistent with studies reporting either a reduction in schizo-
phrenia or no significant difference (Benca et al., 1992; Goder et al.,
2006; Keshavan et al., 1998; Sarkar et al., 2010; Tekell et al., 2005).
Some of these discrepancies may be explained by the medication status
at the time of sleep recordings (Cohrs, 2008). Three meta-analyses have
been published since 1992, the first of which reported a reduction in
REM sleep latency as the only difference in schizophrenia (Benca et al.,
1992). The most recent meta-analysis, which included 31 PSG studies,
showed that several sleep parameters are different in schizophrenia,
i.e., reduced TST and sleep efficiency, increased sleep latency, more
awakenings, and decreased percentage of SWS, REM sleep and REM
sleep latency. However, these differences were dependent on the
medication status and duration of drug withdrawal. Drug-naïve patients
only showed differences in TST, sleep latency and sleep efficiency
(Chan et al., 2017). This is in accordance with another previous meta-
analysis showing that sleep disturbances were more pronounced in
neuroleptic-withdrawn patients compared to drug-naïve patients
(Chouinard et al., 2004). Medication status is therefore a very sig-
nificant factor when considering the expression of sleep disturbances in
schizophrenic patients.
Many studies have investigated sleep spindles and SWA in schizo-
phrenia. Inconsistent findings have been obtained for SWA. By contrast,
a decrease in spindles has been observed in medicated schizophrenia
patients (Ferrarelli et al., 2007, 2010; Manoach et al., 2010; Wamsley
et al., 2012) and in early stage drug-naïve patients (Manoach et al.,
2014), while no differences were observed in drug-withdrawn patients
(Forest et al., 2007; Poulin et al., 2003; Van Cauter et al., 1991). This
suggests that spindles may be an early biomarker or endophenotype of
schizophrenia (Ferrarelli and Tononi, 2017).
4.2.3. Circadian alterations
Highly abnormal timing of sleep has been observed in approxi-
mately half of schizophrenic patients, with many patients not waking
up before ∼15:00 (Wulff et al., 2012). Abnormalities in physiological
markers of the circadian timing system have also been reported in
schizophrenia. Melatonin levels are decreased in schizophrenia suf-
ferers compared to healthy subjects (Fanget et al., 1989; Vigano et al.,
2001) and have been observed in both medication-naïve and medicated
patients (Anderson and Maes, 2012; Monteleone et al., 1992). As to the
causes of this abnormal circadian rhythmicity, it should be kept in mind
that many schizophrenia sufferers are unemployed and socially with-
drawn. The absence of social constraints on sleep timing may lead to
reduced exposure to daylight- the major synchroniser of the human
circadian timing system- that may exacerbate circadian disturbance
(Skeldon et al., 2017). In a study in which schizophrenia patients were
compared to unemployed healthy controls, circadian alterations as as-
sessed by actigraphy were nevertheless observed in the patients (Wullf
et al., 2012).
4.2.4. Other sleep disorders
Prevalence of insomnia is high and variable in schizophrenia, ran-
ging from 19% to 100% depending on inclusion criteria and definition
of insomnia (Kaskie et al., 2017). A particularly comprehensive over-
view of this topic can be found in a review by Reeve and colleagues
(Reeve et al., 2015). Most recently, a prevalence of 25% for DSM-5
Insomnia Disorder in a population of schizophrenia outpatients was
reported (Seow et al., 2018). Several studies suggest that insomnia is a
predictor of paranoia and hallucinations (reviewed in Reeve et al.,
2015), and may be associated with increased risk of suicide (Li et al.,
2016). Most studies of insomnia in schizophrenia have focused on its
association with the first psychotic episode (Krystal, 2012; Davies et al.,
2017). In addition to insomnia, prevalence of OSA and sleep-related
movement disorders in schizophrenia has been investigated (for review:
Cohrs, 2008; Davies et al., 2017; Gupta and Simpson, 2015; Kaskie
et al., 2017; Klingaman et al., 2015; Myles et al., 2016). While many
conflicting data are available, a meta-analysis showed a ∼15% pre-
valence of OSA in schizophrenia patients (Stubbs et al., 2016) which is
not very different from the prevalence in the general population al-
though prevalence rates are critically dependent on diagnostic criteria
and sensitivity of sensors, which continue to change (Heinzer et al.,
2016). Although most clinicians report sleep disturbance in psychotic
patients (Rehman et al., 2017), more systematic screening may provide
insight allowing the tailoring of treatments of sleep disturbance to
improve delusions (Soehner et al., 2013; Spiegelhalder et al., 2013;
Waters et al., 2015).
4.2.5. Effects of antipsychotic medications on sleep
First and second-generation antipsychotics act on dopaminergic,
serotonergic, α-adrenergic, cholinergic and histaminergic receptors, all
of which have been implicated in control of sleep. The effects of anti-
psychotics on sleep-wake disturbance have been reviewed elsewhere
(Cohrs, 2008; Schweitzer and Randazzo, 2016). As mentioned above, a
recent meta-analysis demonstrated that medication status, as well as
duration of the drug-withdrawal period have a significant impact on
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sleep in schizophrenia patients (Chan et al., 2017). Therefore, reported
abnormalities of REM sleep and SWS in schizophrenia may be caused by
medication rather than the disease itself.
4.2.6. Effects of sleep medications in schizophrenia
Pharmacological treatment and management of sleep disorders in
schizophrenia have also received some attention (Gupta and Simpson,
2015; Kaskie et al., 2017; Klingaman et al., 2015). Medications to treat
sleep disorders in schizophrenia include antipsychotics, hypnotic drugs
and melatonin. While some sleep disturbance such as insomnia may be
improved, others, such as sleep movement disorder may be ex-
acerbated, due to the action of antipsychotics on dopamine D2 re-
ceptors (Kaskie et al., 2017).
4.3. Comparison of sleep disturbance between Alzheimer’s disease and
schizophrenia
When comparing sleep disturbance in AD and schizophrenia, there
are very few ideal studies upon which to base conclusions. This is be-
cause of lack of standardisation of tools used to assess both subjective
and objective sleep disturbance across each disease. For example, many
assessments of subjective sleep disturbance are based questionnaires
deliberately tailored to specific patient populations. Researchers in AD
and schizophrenia may also emphasize different aspects of sleep when
analysing data. For example, sleep spindles have received a lot of at-
tention in schizophrenia but few AD researchers have focussed on this.
Any attempt to compare sleep disturbance across disorders or to cor-
relate with other symptoms will not be possible in the absence of
standardisation. Another caveat in the comparison of sleep disturbance
between AD and schizophrenia is the difference in the average age of
these patient populations, with AD patients obviously being on average
much older. Ageing is associated with major changes in sleep timing
and sleep structure even in healthy individuals. Even if sleep in AD and
schizophrenia are compared to age-matched controls it cannot be ex-
cluded that disease specific changes are not confounded by age differ-
ences. A final limitation of existing datasets is that changes in sleep are
often presented in terms of statistical significance rather than in terms
of effect sizes. The latter presentation would allow for a comparison of
the magnitude of the observed effects in AD and schizophrenia.
Despite the limitations of existing datasets, several patterns emerge
when comparing sleep-wake disturbance between AD and schizo-
phrenia. Commonalities in sleep disturbance between AD and schizo-
phrenia include sleep fragmentation, changes in sleep timing and cir-
cadian rhythm alterations. Reductions in SWS are reported in both
conditions, although not in all studies. Differences between AD and
schizophrenia are observed for clinical sleep disorders, with OSA being
much more prevalent in AD while insomnia may be more prevalent in
schizophrenia. However, the robustness of this conclusion is limited
because insomnia as a complaint has not actually been assessed often in
AD. Changes in sleep spindles are more often reported in schizophrenia,
but this may in part reflect researcher bias. Altogether, the most pro-
minent difference between AD and schizophrenia concerns REM sleep.
REM sleep is often reported to be reduced, and in no single study has an
increase in REM sleep been reported in AD, whereas in all but one
schizophrenia study REM sleep was unchanged. This difference be-
tween AD and schizophrenia is unlikely to be related to medication
because it was also observed when only considering drug free studies.
4.4. Contribution of sleep disturbance to other neuropsychiatric symptoms
Given the well-established detrimental impact of sleep fragmenta-
tion and sleep restriction on mood, attention and cognition in healthy
individuals (Lowe et al., 2017), the question arises whether sleep dis-
turbance correlates with NPS in AD and schizophrenia. Potentially,
sleep disturbance may emerge before clinical diagnosis and could cor-
relate with early symptoms. By preceding more traditional symptoms,
sleep disturbance may thereby be considered a predictive biomarker of
the diseases. Sleep disturbance may also be associated with symptoms
during the disease, remission, or predict relapse in the case of schizo-
phrenia.
4.4.1. Alzheimer’s disease
Sleep disruption leads to a higher risk of developing cognitive im-
pairment and dementia (Benedict et al., 2015; Bubu et al., 2017) and
the severity of sleep disruption is associated with the severity of de-
mentia (Moe et al., 1995; Pat-Horenczyk et al., 1998). Some cross-
sectional studies report an inverted U-shaped profile, with moderate AD
patients having more impaired sleep than patients in early or advanced
stages (McCurry et al., 2000; van Someren et al., 1996). A recent po-
pulation-based prospective study demonstrated that shorter REM sleep
percentages and longer REM latencies several years prior to the in-
cidence of dementia are both independently related with a higher risk
for developing AD, while NREM sleep parameters showed no such as-
sociations (Pase et al., 2017). Each percentage reduction in REM sleep
was associated with an approximate 9% increase in dementia risk, even
after applying adjustments for vascular risk factors, depression, and
medication use. REM sleep disruption during preclinical AD progression
may therefore be underrated as a prognostic biomarker. A longitudinal
study recently demonstrated that reduced REM sleep (and increased
Stage 1 [N1]) was also a predictor of cognitive decline in non-demented
older men (Song et al., 2015). In a cross-sectional analysis of the as-
sociation between sleep and cognition in healthy men and women aged
20-84, it was found that REM sleep as well as sleep continuity were
associated with maintained ‘accuracy’ and executive function (Della
Monica et al., 2018).
Few studies have performed simultaneous assessment of sleep and
other neuropsychiatric variables in AD (Lanctot et al., 2017) (Tables
1–4). Sleep disturbance, total Pittsburgh Sleep Quality Index, sleep
duration, time in bed at night and number of awakenings in AD were
positively associated with apathy, the most frequently reported NPS in
this disorder (de Oliveira et al., 2014; Mulin et al., 2011; Shin et al.,
2014). In fact, assessment of 24-h rest-activity patterns by actigraphy
permits diagnosis of apathy in AD patients (Zeitzer et al., 2013). Sleep
disruption accompanied with apathy was identified as a strong pre-
dictor of functional impairment in AD (You et al., 2015). AD patients
presenting with sleep disturbance can also display aggressiveness/agi-
tation, and other daytime behavioural issues although the robustness of
this association remains unclear. Daytime sleepiness and napping were
associated with more profound functional impairments including gen-
eral cognitive, intellectual and abstractive function, verbal memory and
fluency, spatial and visual memory, in mild and moderate AD patients
(Bonanni et al., 2005). Sleep disturbance also associated with the extent
to which behavioural symptoms negatively impacted the patients or
caregivers (Moran et al., 2005; Rebok et al., 1991).
A decrease in the robustness of circadian rhythms in activity or
delayed rhythms have also been associated with an increased risk to
develop dementia (Tranah et al., 2011). In terms of the relationship
between sleep disruption and cognitive function, sleep disturbance in
AD is associated with greater cognitive decline (Blackwell et al., 2014;
Lim et al., 2013; Spira et al., 2014) and the onset of AD was at a
younger age in patients with OSA (Osorio et al., 2015). The degree of
reduction in spindle density in mild cognitive impairment and AD
correlates with the severity of memory impairment (Gorgoni et al.,
2016; Westerberg et al., 2012). Overall it can be concluded that despite
the lack of systematic large-scale studies with standardised methodol-
ogies, there is emerging evidence for an association between sleep
disturbance and neuropsychiatric symptoms in AD. Further standardi-
sation of methodology may lead to more specific conclusions about the
nature and extent of these associations.
4.4.2. Schizophrenia
Social withdrawal is a common neuropsychiatric symptom in
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schizophrenia and long time in bed periods and abnormal sleep-wake
timing may be an expression of this, even before a diagnosis is made.
For example, in socially withdrawn young individuals of whom 37%
were ultimately diagnosed with schizophrenia and related disorders,
disorders of the sleep-wake schedule were very common (> 70%)
(Chauliac et al., 2017). The association between PSG-assessed sleep
characteristics, psychosis and positive psychotic symptoms has been
investigated both in populations at risk as well as clinical cohorts
(Reeve et al., 2015; Sarkar et al., 2010). The most consistent findings in
these studies were the positive associations between indices of in-
creased REM sleep propensity (shorter REM latency, more REM sleep)
and positive psychotic symptoms (Poulin et al., 2003; Sarkar et al.,
2010; for review Reeve et al., 2015), although this finding may be
specific to medicated patients. Fewer studies have investigated the re-
lationship between SWS and NPS in schizophrenia, and in several of
these studies patients were medicated. SWS was reported to be in-
versely correlated with negative symptoms encompassing emotional
withdrawal, blunted affect and poverty of speech (Keshavan et al.,
1995, 1996). Some studies document a correlation between spindle
reduction in schizophrenia and the severity of psychosis (Ferrarelli
et al., 2010; Manoach et al., 2004, 2014; Wamsley et al., 2012; for
review Ferrarelli and Tononi, 2017; Manoach et al., 2016). Further-
more, reductions in sleep spindles in NREM sleep correlated with im-
paired attention, poor performance in motor sequence, working
memory, and declarative memory tasks in schizophrenic patients
(Buchmann et al., 2014; Goder et al., 2015; Keshavan et al., 2011;
Wamsley et al., 2012). Interestingly, impairments in a verbal learning
and memory test were also related to sleep spindle activity in first-de-
gree relatives of schizophrenia patients (Schilling et al., 2017). Overall,
it can be concluded that many studies in schizophrenia report asso-
ciations between aspects of sleep and other neuropsychiatric symptoms
although the specificity and consistency of these associations and their
dependency on medication status requires further investigation. Major
limitations of the current studies concern the lack of standardisation
across disorders, absence of longitudinal data and lack of unbiased
approaches for the measurement of many sleep parameters. The
available data nevertheless demonstrate the potential of investigating
associations between sleep disturbance and neuropsychiatric symptoms
in AD and schizophrenia.
4.5. Sleep disturbance in preclinical models of Alzheimer’s disease and
schizophrenia
A number of preclinical rodent models of AD and schizophrenia
have been developed. Preclinical models of AD typically involve the
experimental induction of either β-amyloid (Aβ) and/or tau pathology.
Sleep studies in these AD models have documented a reduction in TST,
NREM and REM sleep duration (Table 5). In several studies it was re-
ported that sleep alterations arose prior to significant deposition of
plaques and tangles and in some studies "rescue treatment" attenuated
the sleep alterations (Table 5). As a result of these findings, more work
should be done to consider whether sleep may be a biomarker in early
disease stages and/or potentially a marker of reversal of pathology.
Fewer studies have evaluated sleep in schizophrenia models. These
models target a broader variety of mechanisms including prenatal de-
velopment, the vasoactive intestinal peptide receptor, or gene loci in-
volved in schizophrenia (e.g., "Disrupted in schizophrenia 1" (DISC1);
(Table 6). A decrease in NREM sleep and REM sleep and increase in
sleep fragmentation was observed in most of these studies (Table 6). In
some of the animal models specific EEG oscillations, such as ripples and
gamma activity, were quantified. Despite being implicated in memory
consolidation and cognition, these oscillations are not easy to measure
in human studies.
Overall, when it has been assessed, studies of sleep in preclinical
models of AD and schizophrenia demonstrate sleep disturbances.
Comparisons across preclinical models and patient studies are
hampered by different terminology and analysis methods. Nevertheless,
the commonality of the neurobiological mechanisms underlying sleep
and the prospect of comprehensive and longitudinal monitoring of this
state does identify sleep as a promising target for furthering our un-
derstanding of psychiatric disorders.
5. Mechanisms linking sleep disturbance to NPS in AD and
schizophrenia
The contribution of sleep to brain function has received consider-
able attention during the past decades and there is considerable evi-
dence that sleep contributes to alertness, mood, sustained attention and
memory consolidation. However, there is no consensus on how sleep
exerts these positive effects. Several hypotheses have been proposed,
and this section considers some of the putative mechanisms through
which sleep may contribute to core and other neuropsychiatric symp-
toms in AD and schizophrenia.
5.1. Cellular mechanisms
Perhaps the most obvious mechanism to consider is that sleep dis-
turbance directly influences the progression of molecular pathology in
AD. Evidence for this hypothesis comes from both clinical and pre-
clinical research. For instance, in the early stages of AD, Aβ levels in
CSF display a diurnal rhythm, rising during wake and decreasing during
sleep (Huang et al., 2012). Poor sleep in cognitively preserved adults
with a parental history of sporadic AD correlates with higher levels of
CSF biomarkers for AD, including Aβ42 and hyperphosphorylated tau
(Sprecher et al., 2017). Both of these findings suggest a potential re-
lationship between sleep and amyloid pathology per se in humans. Si-
milar changes are observed in rodent models. Manipulations such as
chronic sleep restriction increase amyloid plaque deposition in an
amyloid mouse model, while chronic treatment with a dual orexin
antagonist (used clinically as a sleep-promoting agent) reduces plaque
burden (Kang et al., 2009). Longitudinal studies of a number of dif-
ferent AD mouse models (i.e. PDAPP, App Swe/PS1, triple transgenic
hAPP/hTau/hPS1 mice) identify sleep and/or circadian alterations
prior to the deposition of neuropathological hallmarks. Some of these
preclinical transgenic sleep and circadian phenotypes replicate the
sleep changes observed in AD sufferers (Table 5). Furthermore, injec-
tion of Aβ oligomers into the brains of such mice disrupt rest-activity
patterns as well as their ability to perform cognitive tasks (Kincheski
et al., 2017). These preclinical studies suggest that sleep and circadian
disturbance may directly influence the rate of progression of patholo-
gical deposition in AD (Lucey and Bateman, 2014), although one major
limitation of this field is the sparseness of published literature. Very few
preclinical studies have concomitantly assessed sleep disturbance with
behavioural phenotypes, be they cognitive or otherwise, and then at-
tempted to relate these measurements to synaptic integrity.
One cellular mechanism by which sleep may interact with protein
pathologies in AD lies in its putative physiological role in solute
clearance, via the recently described glymphatic pathway (Smith and
Verkman, 2018). This system provides active fluid transport dependent
on aquaporin-4 channels through the brain (Iliff et al., 2012). An im-
portant recent paper used accumulation of tracer compounds to suggest
that glymphatic clearance is more effective during sleep relative to
wake (Xie et al., 2013). This group then went on to suggest that
glymphatic clearance during sleep contributes to the removal of toxic
species, such as Aβ, accumulated during waking and further docu-
mented that sleep posture (lateral vs prone) had a substantial impact on
the efficiency of this process in rodents (Lee et al., 2015). The glym-
phatic hypothesis remains somewhat controversial with other studies
challenging this notion (Smith and Verkman, 2017; Smith et al., 2017).
Several lines of evidence showed that clearance of β-amyloid occurs at
the level of brain capillaries (Hartz et al., 2018, 2016; Storck et al.,
2016). Recently, a critical role of meningeal lymphatic vasculature was
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uncovered in the accumulation of parenchymal deposition of β-amyloid
in mouse models of Alzheimer’s disease (Da Mesquita et al., 2018).
Sleep and sleep loss has also been related to activity of the unfolded
protein response (UPR) (Brown et al., 2017). Dysfunction of the UPR
has been implicated both in the neurodegenerative process of AD and in
schizophrenia (Xiang et al., 2017). Interestingly, drugs which modulate
UPR activation have been shown to not only reverse cognitive deficits
but also to reduce hippocampal atrophy in a dementia mouse model
(Halliday et al., 2017).
5.2. Neurotransmitter alterations
Specific neurotransmitter activities may also link sleep disturbance
to the incidence of NPS in AD. Alterations in REM sleep parameters
have often been ascribed to cholinergic deficits that are typically ob-
served in AD (reviewed in Peter-Derex et al., 2015; Petit et al., 2004).
However, it should be noted that the neurochemical regulation of REM
sleep involves a variety of other neurotransmitter systems (Luppi et al.,
2017; Saper and Fuller, 2017; Vetrivelan et al., 2016) and changes in
REM sleep are therefore not necessarily primarily related to changes in
the cholinergic system. An important neurotransmitter system in this
context might be the orexin/hypocretin system, one of the key wake-
promoting systems in the brain. Saporin lesions of orexin-producing
neurons strongly implicate this system in behaviours related to arousal,
attention and motivation, as well as goal-oriented behaviours (Boutrel
et al., 2010; Wheeler et al., 2014). Clinically, moderate to severe AD
patients display elevated orexin levels in CSF, associated with total tau
levels and sleep impairment (Liguori et al., 2014), specifically REM
sleep reduction (Liguori et al., 2016). Orexin antagonists increase REM
sleep in both rodents and humans (Bettica et al., 2012; Gotter et al.,
2016). Recent studies demonstrated that the effects of orexin antago-
nists on REM sleep were not mediated by basal cholinergic neurons
(Schwartz et al., 2016; Vazquez-DeRose et al., 2016) and increases in
orexin in AD may well be related to reductions in REM sleep in this
patient group (Bettica et al., 2012; Gotter et al., 2016). As mentioned
above, transgenic APPswe/PS1dE9 mice treated with a dual orexin
receptor antagonist showed a reduced Aβ plaque burden (Kang et al.,
2009). These data imply that imbalance in the orexinergic system has
the potential to contribute to sleep disruption in AD which may thereby
affect disease progression.
Compared to AD, the multitude of genetic risk variants (Devor et al.,
2017) and lack of any definitive causal mechanism in schizophrenia
makes it much harder to address the question of the mechanistic links
between sleep disturbance and NPS. However, monoaminergic circuits
clearly play an important role, with the majority of clinically effective
antipsychotic agents targeting blockade of dopamine, serotonin and
histamine receptors. The heightened arousal state commonly observed
in schizophrenia patients suggests an underlying issue with arousal
control, which may be related to monoaminergic function. Recent
evidence using optogenetic techniques has demonstrated an important
role of the ventral tegmental area and specifically dopaminergic neu-
rons in controlling wakefulness, motor function and wake-related be-
haviours (Eban-Rothschild et al., 2016). Moreover, dopaminergic,
noradrenergic and serotonergic transmission, as well as the dorsolateral
prefrontal circuit, are common neural pathways contributing to nega-
tive symptoms and commonly implicated in both dementia and schi-
zophrenia (Reichman and Negron, 2001; Winograd-Gurvich et al.,
2006). More specific genetic studies in this context are quite rare, al-
though a recent study of a human 5HT2B receptor mutation (HTR2B
Q20*) indicated a link to impulsivity and incidence of early onset
schizophrenia (Bevilacqua et al., 2010). By way of comparison, 5HT2B
knockout mice demonstrate deficits in sensorimotor gating, selective
attention, cognition and social interaction, as well as enhanced re-
sponse to psychostimulants (Pitychoutis et al., 2015). These animals
also displayed disrupted sleep, with decreases in the amount of NREM
sleep and reduced REM latency. Sleep fragmentation effects inTa
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schizophrenia patients (Wulff et al., 2012) have been recapitulated in a
mouse model with disrupted synaptosomal-associated protein (SNAP-
25), a gene that has been associated with schizophrenia (Oliver et al.,
2012). Otherwise, non-transgenic animal models (Table 6), such as
those that affect early brain development, have proved more useful in
identifying phenotypic changes similar to those in schizophrenia (Lodge
and Grace, 2009). Investigation of sleep-wake activity in the methyla-
zoxymethanol acetate (MAM) model revealed fragmentation of sleep
and a decoupling of sleep spindles and hippocampal ripples (Phillips
et al., 2012a,b), in addition to cognitive and anatomical changes ob-
served in schizophrenia (Brown et al., 2012).
5.3. Mnemonic and cognitive processes
When evaluating mechanisms relating sleep disturbance and NPS,
the potential importance of sleep and its phenomenology for cognitive
processing and memory consolidation cannot be ignored (Dudai et al.,
2015; Vorster and Born, 2015). Sleep may provide a window for sy-
naptic homeostasis to occur, a hypothetical process whereby synaptic
weights that have altered as a function of experience and learning
through the day are renormalized, allowing selected synapses to be
strengthened whilst others are depressed (Cirelli and Tononi, 2011).
Both NREM and REM sleep processes likely play a role in synaptic
homeostasis and memory consolidation (see e.g., Ritter et al., 2015),
although NREM sleep has received more study in this context. During
NREM sleep, two electrophysiological signatures known as sleep spin-
dles and hippocampal ripples occur (Buzsaki, 1998; Siapas and Wilson,
1998; Wei et al., 2016). Sleep spindles are bursts of 12–16 Hz activity
that originate in thalamic nuclei and can be relayed throughout the
cortex as slow wave oscillatory activity. Recent evidence from human
electrophysiological recordings demonstrate a strong link between
thalamic spindles and cortical down-states (Mak-McCully et al., 2017).
Sleep spindle activity also coordinates with and potentially determines
the expression of hippocampal ripples, bursts of high frequency (ro-
dents:∼140-180 Hz; humans: 80-100 Hz) neuronal network activity
that may represent compressed neuronal firing sequences from earlier
periods during waking. In rodents, there has been much focus on hip-
pocampal spatial memory as a model for exploring the role of slow
waves and spindles in memory consolidation. These types of oscillatory
activity provide optimal conditions for transfer of information from
hippocampus to cortex (Maingret et al., 2016), and disruption of hip-
pocampal ripples will result in memory impairments in animal models
(Sara, 2017; Latchoumane et al., 2017). Spindles and SWA have been
proposed to contribute to mechanisms underlying cognitive impairment
and/or Aβ pathology (Kang et al., 2009; Mander et al., 2016; Roh et al.,
2012). However, like many of the other mechanisms described in this
section, the study of spindle-ripple activity in the context of AD and
schizophrenia has been very limited. In patients with mild cognitive
impairment, stimulation of cortical slow oscillations using transcranial
stimulation during sleep enhanced synchronization of slow oscillations
and spindle power and was able to boost cognitive function
(Ladenbauer et al., 2017). Similarly, cortico-thalamic network dys-
function has been suggested as a target mechanism amenable to mod-
ulation by transcranial stimulation in schizophrenia (Pinault, 2017). In
schizophrenia, the genetic risk factor CACNA1-I encodes a calcium
channel highly expressed in the thalamic circuits that generate spindles
(Manoach et al., 2016), suggestive of a mechanistic link worthy of
further investigation. A recent study showed an association between
CACNA1-I and sleep spindles in healthy adolescents (Merikanto et al.,
2018). Other mechanisms potentially involved in sleep-related memory
consolidation processes include the cyclic adenosine monophosphate
(cAMP) and mammalian target of rapamycin (mTOR) signalling
(Havekes and Abel, 2017), as well as changes in synaptic function and
structure (de Vivo et al., 2017; Raven et al., 2018).
Despite early work suggesting an important role for REM sleep in
memory consolidation processes (Scullin and Bliwise, 2015; Siegel,
2001), much less attention has been devoted to this topic. In mice,
optogenetic disruption of EEG theta activity in the medial septum
during REM sleep led to impairment of consolidation of spatial memory
and fear-conditioned contextual memory (Boyce et al., 2016). A re-
quirement for REM sleep in the consolidation of learning related to
danger and the extinction of fear responses has also been documented
in humans (Menz et al., 2016). There is growing evidence that REM
sleep may specifically impact consolidation of emotional memories by
contributing to the resolution of distress related to such experiences
(Wassing et al., 2016).
If sleep is fundamentally important for the stability of cognitive
processes, it follows that a loss of sleep will be significantly detrimental
to normal behaviour, a finding consistently confirmed by studies of
sleep restriction in humans. Meta-analysis suggests that sleep loss may
affect several neurocognitive functions, particularly those related to
sustained attention and executive function (Lowe et al., 2017). Fur-
thermore, insomnia-like experimental sleep restriction paradigms can
facilitate the development of psychotic experiences in human volun-
teers (Reeve et al., 2012). Sleep disruption can induce paranoia, hal-
lucinations, psychosis, cognitive disorganisation and working memory
impairment. It can also be associated with increase in negative affect,
depression, anxiety and stress (Reeve et al., 2012). Several fMRI studies
in humans have suggested that sleep deprivation decreases encoding-
related activities in the hippocampus, as well as connectivity to related
areas of the cortex. Working memory dependent activity within the
default mode network has been suggested to become unstable following
sleep deprivation (Gujar et al., 2010). In sleep deprived healthy in-
dividuals, increases in net synaptic strength and decreased ability to
induce Long-Term Potentiation (LTP)-like plasticity has been observed,
supporting the hypothesis that sleep loss will result in failure to reset
associative synaptic plasticity (Kuhn et al., 2016). One significant lim-
itation is that human studies have so far focussed on the effects of a
single night of sleep deprivation. Few have studied the effects of im-
paired sleep continuity or less acute disruption over a longer period. It
should also be noted that there is considerable individual variability in
response to sleep deprivation, the extent to which depends on the
cognitive parameter being assessed (Frey et al., 2004).
In summary, during sleep several plausible cellular mechanisms,
including glymphatic clearance and the UPR, have been described that
may directly affect pathology of AD and perhaps schizophrenia. Many
of the neurotransmitter systems involved in the regulation of sleep-
wake activity are also directly impacted by each disease process and/or
impacted by pharmacological treatments used. Specific aspects of sleep
may also be directly involved in the effective processing of memories
and learning events. Thus, if sleep is disturbed as a function of disease
process, be it a timing, continuity or specific sleep stage disturbance,
then this has the potential to impact upon cellular, synaptic and psy-
chological processes that may then exacerbate disease. Datasets are
promising but limited in this context and further elucidation of the
relative contribution of specific aspects of sleep disturbance to each
potential mechanism requires a neuroscience-oriented approach in both
preclinical and clinical sleep research.
6. Perspectives and conclusions
This review has highlighted that there are several potentially im-
portant differences regarding the expression of sleep disturbance be-
tween AD and schizophrenia, and that not all patients may be affected
equally by these symptoms. However, an ability to use this data to re-
fine diagnosis of patients is greatly hampered by simple conceptual and
operational problems. To further investigate the association between
sleep disturbance, NPS and cognitive deficits in CNS disorders such as
AD and schizophrenia, it will be important to improve several metho-
dological aspects.
1 Implementation and validation of simultaneous assessment of
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sleep/circadian parameters and neuropsychiatric symptoms.
This is a prerequisite to explore the interrelations between para-
meters such as TST, excessive daytime sleepiness and symptoms
such as social withdrawal and apathy. Basic validation of specific
test instruments for use in each specific disease state is often lacking.
2 Standardisation of commonly used descriptors of sleep dis-
turbance. TST, which is one of the most basic measures of sleep
behaviour may in some studies refer to the duration of PSG de-
termined sleep during a laboratory session scheduled between
11 pm and 7am and in other studies refer to self or carer reported ad
libitum nocturnal and diurnal sleep. Development of standardised
reporting tools of nocturnal and diurnal sleep and wider im-
plementation of actigraphy will greatly aid the quantification of
sleep and circadian disturbance. Standardisation should extend to
preclinical studies.
3 Standardisation of PSG based assessments of sleep. PSG studies
performed in AD and schizophrenia have been primarily laboratory-
based. To avoid the biases associated with laboratory studies and
their scheduling constraints, development and implementation of
new portable technology to record EEG using reduced montages in
the home environment is needed (Bleichner and Debener, 2017;
Lucey et al., 2016; Radha et al., 2014). Additionally, many PSG
studies focus on one single aspect of sleep phenomenology (e.g.,
SWS, spindles), and neglect other changes that may be happening.
Better quantification of REM sleep in this context may be critical
given the potential difference between AD and schizophrenia, al-
though most recent literature does not even make a distinction be-
tween phasic and tonic REM sleep. Standardisation should extend to
preclinical studies.
4 Standardisation of screening for co-morbid sleep disorders.
Screening for sleep disorders such as sleep apnoea, periodic limb
movements and insomnia should be part of the basic screening
battery in any protocol assessing neuropsychiatric parameters in AD
and schizophrenia. Sleep disorders may be differentially associated
with each disease and thereby complicate any attempt to reclassify
patients according to other objective biological parameters.
5 Wider application of quantitative EEG analysis approaches.
Higher density EEG recordings may be useful for the detection of
local/topographical aspects of sleep. Longitudinal sleep recordings
may capture the disorder trajectory more effectively and potentially
help resolve subtypes of patients currently diagnosed with AD or
schizophrenia. Secondary analyses such as the link between the
waking EEG and the sleep EEG, coherence, global field synchroni-
sation, connectivity, network properties, should provide valuable
information and potentially provide insights into causative pathway
contributing to the overlap with other neuropsychiatric symptoms.
6 Analyses of other physiological variables that change with
sleep. For example, measurement of parameters such as heart rate,
parasympathetic versus sympathetic tone are needed to capture the
influence of sleep disturbances on physiological processes which
may impact on the restorative function of sleep.
Attempting to differentiate AD and schizophrenia patients pre-
senting clear sleep and circadian disruption from those with less pro-
nounced disruption may provide insights into the association with other
neuropsychiatric and cognitive symptoms in these disorders. Efforts like
the PRISM initiative (Kas et al. 2018, this issue) need to consider
standardised collection of sleep parameters as being core to any attempt
to objectively reclassify psychiatric and neurological disorders. Gaining
further insights into the nature and extent of sleep disturbance in psy-
chiatric and neurological disorders may have direct beneficial effects of
the management of these disturbances. This should increase not only
the quality of life of patients but also of their caregivers. It may offer
insights into novel mechanisms and targets for drug development not
only to delay but also to potentially prevent disease development and
non-pharmaceutical interventions to neuropsychiatric and cognitive
deficits in these disorders. Such approaches may not only lead to a
better understanding of the association between sleep and brain func-
tion in these patient populations but also provide clues to the me-
chanisms by which sleep contributes to brain health across the lifespan.
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